19178-11-1 Usage
Uses
Used in Pharmaceutical Industry:
7,8-dimethoxyquinazolin-4(3H)-one is used as a therapeutic agent for its anti-inflammatory properties, potentially aiding in the treatment of various inflammatory conditions. Its antitumor properties make it a candidate for cancer research and treatment, targeting the inhibition of tumor growth and progression. Additionally, its antiviral properties suggest its use in developing treatments for viral infections.
Used in Medicinal Chemistry Research:
7,8-dimethoxyquinazolin-4(3H)-one serves as a key building block in the synthesis of other biologically active compounds, contributing to the discovery and development of new pharmaceuticals with diverse therapeutic applications.
Used in Drug Synthesis:
As a versatile chemical compound, 7,8-dimethoxyquinazolin-4(3H)-one is utilized in the synthesis of various drugs, enhancing the development of novel therapeutic agents with improved efficacy and selectivity in treating specific diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 19178-11-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,1,7 and 8 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 19178-11:
(7*1)+(6*9)+(5*1)+(4*7)+(3*8)+(2*1)+(1*1)=121
121 % 10 = 1
So 19178-11-1 is a valid CAS Registry Number.
19178-11-1Relevant academic research and scientific papers
Small-molecule phosphodiesterase probes: Discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1
Humphrey, John M.,Yang, Eddie,Ende, Christopher W. Am,Arnold, Eric P.,Head, Jenna L.,Jenkinson, Stephen,Lebel, Lorraine A.,Liras, Spiros,Pandit, Jayvardhan,Samas, Brian,Vajdos, Felix,Simons, Samuel P.,Evdokimov, Artem,Mansour, Mahmoud,Menniti, Frank S.
, p. 1290 - 1296 (2014/10/15)
PDE1 is a family of calcium-activated, dual substrate phosphodiesterases expressed in both the CNS and periphery that play a role in the integration of intracellular calcium and cyclic nucleotide signaling cascades. Exploration of the potential in targeting this family of enzymes to treat neuropsychiatric disorders has been hampered by a lack of potent, selective, and brain penetrable PDE1 inhibitors. To identify such compounds we used high-throughput screening, structure-based design, and targeted synthetic chemistry to discover the 4-aminoquinazoline 7a (PF-04471141) and the 4-indanylquinazoline 27 (PF-04822163) each of which are PDE1 inhibitors that readily cross the blood brain barrier. These quinazoline-based PDE1-selective inhibitors represent valuable new tools to study the biological processes regulated by PDE1 and to begin to determine the potential therapeutic utility of such compounds to treat neuropsychiatric disorders.
